Novel dipeptidyl peptidase-4-inhibiting peptide derived from β-lactoglobulin

Journal of Pharmacological Sciences

Volumn 117, Issue 1, 2011, Pages 63-66

  Uchida, Masayuki ^a   Ohshiba, Yukio ^a   Mogami, Orie ^a  

^a MEIJI DAIRIES CORPORATION   (Japan)

Author keywords

DPP 4 inhibitor; Val Ala Gly Thr Trp Tyr; lactoglobulin

Indexed keywords

BETA LACTOGLOBULIN; DIPEPTIDYL PEPTIDASE IV; GLUCOSE; SITAGLIPTIN; TRYPSIN;

ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; IC 50; IN VITRO STUDY; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST;

EID: 80052897910     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.11089SC     Document Type: Article

References (15)

1. Nauck MA, Baller B, Meier JJ. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes. 2004;53 Suppl 3:S190-S196.
2. Meier JJ, Gallwitz B, Kask B, Deacon CF, Holst JJ, Schmidt WE, et al. Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects. Diabetes. 2004;53 Suppl 3:S220-S224.
3. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86:3717-3723. (Pubitemid 32755966)
4. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50:609-613. (Pubitemid 32195226)
5. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagonlike peptide-1 7-36: a physiological incretin in man. Lancet. 1987;2:1300-1304.
6. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab. 1995;80:952-957.
7. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993;214:829-835.
8. Vilsbøll T, Agerso H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab. 2003;88:220-224. (Pubitemid 36115169)
9. Luhovyy BL, Akhavan T, Anderson GH. Whey proteins in the regulation of food intake and satiety. J Am Coll Nutr. 2007;26:704S-712S.
10. Yamaguchi M, Yoshida K, Uchida M. Novel functions of bovine milk-derived alpha-lactalbumin: anti-nociceptive and anti-inflammatory activity caused by inhibiting cyclooxygenase-2 and phospholipase A2. Biol Pharm Bull. 2009;32:366-371.
11. Östman EM, Elmståhl HGML, Björck IME. Inconsistency between glycemic and insulinemic responses to regular and fermented milk products. Am J Clin Nutr. 2001;74:96-100. (Pubitemid 32574916)
12. Nilsson M, Stenberg M, Frid AH, Holst JJ, Björck IME. Glycemia and insulinemia in healthy subjects after lactose equivalent meals of milk and other food proteins: the role of plasma amino acids and incretins. Am J Clin Nutr. 2004;80:1246-1253. (Pubitemid 41350685)
13. Gannon MC, Nuttall FQ, Krezowski PA, Billington CJ, Parker S. The serum insulin and plasma glucose responses to milk and fruit products in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1986;29:784-791. (Pubitemid 17053715)
14. Frid AH, Nilsson M, Holst JJ, Björck IM. Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects. Am J Clin Nutr. 2005;82:69-75. (Pubitemid 41716379)
15. Tulipano G, Sibilia V, Caroli AM, Cocchi D. Whey proteins as source of dipeptidyl dipeptidase IV (dipeptidyl peptidase-4) inhibitors. Peptides. 2011;32:835-838.